Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 146 ()

DOP045

Self-administered telemedicine empowers paediatric and adolescent patients with Inflammatory Bowel Disease

Year: 2016
Authors:

K. Carlsen*1, 2, C. Jakobsen2, L. F. Hansen2, A. Paerregaard2, T. Kallemose3, G. Houen4, L.B. Riis5, P. S. Munkholm6, V. Wewer2

1Hvidovre Hospital, Paediatric, Hvidovre, Denmark, 2Hvidovre Hospital, Department of Paediatrics, Hvidovre, Denmark, 3Hvidovre Hospital, Clinical Research Centre and Department of Orthopaedic, Hvidovre, Denmark, 4Statens Serum Institute, Department of Autoimmunology and Biomarkers, Copenhagen, Denmark, 5Herlev Hospital, Department of Pathology, Herlev, Denmark, 6North Zealand Hospital, Department of Gastroenterology, Frederikssund, Denmark

DOP046

Mid- to long-term stability and associated prognostic factors of adalimumab treatment for 1 189 patients with Crohns disease: a multicentre cohort study

Year: 2016
Authors:

H. Tanaka*1, N. Kamata2, A. Yamada3, K. Endo4, T. Fujii5, T. Yoshino6, 7, T. Sugaya8, Y. Yokoyama9, S. Bamba10, J. Umeno11, Y. Yanai12, M. Ishii13, T. Kawaguchi14, S. Shinzaki15, Y. Toya16, T. Kobayashi17, M. Nojima18, T. Hibi17

1Sapporo Kosei General Hospital, IBD Centre, Sapporo, Japan, 2Osaka City University Graduate School of Medicine, Department of Gastroenterology, Osaka, Japan, 3Sakura Medical Centre, Toho University, Department of Internal Medicine, Chiba, Japan, 4Tohoku University Graduate School of Medicine, Division of Gastroenterology, Sendai, Japan, 5Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, 6Graduate School of Medicine, Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan, 7Tazuke Kofukai Medical Research Institute, Kitano Hospital, IBD Centre, Osaka, Japan, 8Dokkyo Medical University, Department of Gastroenterology, Tochigi, Japan, 9Hyogo College of Medicine, Division of Internal Medicine, Department of Inflammatory Bowel Disease, Hyogo, Japan, 10Shiga University of Medical Science, Division of Gastroenterology, Shiga, Japan, 11Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, 12Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan, 13Kawasaki Medical School, Department of Internal Medicine, Division of Gastroenterology, Kurashiki, Japan, 14Tokyo Yamate Medical Centre, Department of Internal Medicine, Division of IBD, Tokyo, Japan, 15Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Osaka, Japan, 16School of Medicine, Iwate Medial University, Division of Gastroenterology, Iwate, Japan, 17Kitasato University Kitasato Institute Hospital, Centre for Advanced IBD Research and Treatment, Tokyo, Japan, 18The Institute of Medical Science, The University of Tokyo, Centre for Translational Research, Tokyo, Japan

DOP047

PYRAMID registry: an observational study of adalimumab in Crohns disease—results at year 7

Year: 2016
Authors:

G. D’Haens1, W. Reinisch*2, J. Satsangi3, E. Loftus Jr4, R. Panaccione5, H. Read6, M. Heinrich7, J. Petersson6, A.M. Robinson6

1Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, 2Medical University of Vienna, Vienna, Austria, 3Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, 4Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, Minnesota, United States, 5University of Calgary, Department of Medicine, Calgary, Canada, 6AbbVie Inc., North Chicago, Illinois, United States, 7AbbVie Deutschland, Ludwigshafen, Germany

DOP048

Delayed response to golimumab therapy: UC patient characteristics and long-term clinical outcome—post-hoc analyses from the PURSUIT programme

Year: 2016
Authors:

J.-F. Colombel*1, W. Reinisch2, P. Gibson3, W. J. Sandborn4, B. Feagan5, S. Xu6, R. Strauss6, H. Zhang6, D. Tarabar7, Z. Hebzda8, P. Rutgeerts9, C. Marano6

1Mount Sinai, Icahn School of Medicine, New York, New York, United States, 2Universitätsklinik für Innere Medizin III and McMaster University, Vienna and Hamilton, Austria, 3Alfred Hospital, Melbourne, Australia, 4University of California San Diego, Division of Gastroenterology, La Jolla, California, United States, 5Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, 6Janssen R & D, LLC, Spring House, Pennsylvania, United States, 7Military Medical Academy, Department of Gastroenterology and Hepatology, Belgrade, Serbia, 8Military Hospital, Krakow, Poland, 9University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands

1University of Cambridge, School of Clinical Medicine, Cambridge, United Kingdom 2Addenbrooke's Hospital NHS Trust, Department of Gastroenterology, Cambridge, United Kingdom 3University of Exeter, Exeter IBD and Pharmacogenetics Research Group, Exeter, United Kingdom 4Royal Devon and Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom 5Nottingham University Hospitals NHS Trust, Department of Gastroenterology, Nottingham, United Kingdom 6St Mark's Hospital, Inflammatory Bowel Disease Unit, London, United Kingdom 7Imperial College, Faculty of Medicine, Department of Surgery & Cancer, London, United Kingdom

DOP048

PROFILE trial: predicting outcomes for Crohn's disease using a molecular biomarker

Year: 2017
Source:

1University of Cambridge, School of Clinical Medicine, Cambridge, United Kingdom 2Addenbrooke's Hospital NHS Trust, Department of Gastroenterology, Cambridge, United Kingdom 3University of Exeter, Exeter IBD and Pharmacogenetics Research Group, Exeter, United Kingdom 4Royal Devon and Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom 5Nottingham University Hospitals NHS Trust, Department of Gastroenterology, Nottingham, United Kingdom 6St Mark's Hospital, Inflammatory Bowel Disease Unit, London, United Kingdom 7Imperial College, Faculty of Medicine, Department of Surgery & Cancer, London, United Kingdom

Authors:

Lee J.1,2, Biasci D.1, Noor N.*1,2, McKinney E.1, Ahmad T.3,4, Lewis N.5, Hart A.6,7, Lyons P.1, Parkes M.1,2, Smith K.1

DOP049

Efficacy and safety of golimumab induction 
for moderate-to-severe ulcerative colitis in 
the United Kingdom: results from the 
GO-COLITIS study

Year: 2016
Authors:

C. Probert*1, D. R. Gaya2, P. J. Hamlin3, P. Irving4, S. Sebastian5, G. Gillespie6, H. Tate6, C. Wheeler6

1University of Liverpool, Liverpool, United Kingdom, 2Glasgow Royal Infirmary, Glasgow, United Kingdom, 3Leeds Teaching Hospitals Trust, Leeds, United Kingdom, 4Guy’s and St. Thomas’ Hospitals, London, United Kingdom, 5Hull & East Yorkshire NHS Trust, Hull, United Kingdom, 6MSD UK, Hoddesdon, United Kingdom

1KULeuven, Translational Research in Gastrointestinal Disorders (TARGID), Clinical and Experimental Medicine, Leuven, Belgium 2KULeuven, Laboratory of Hepatology, Clinical and Experimental Medicine, Leuven, Belgium 3UZLeuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 4KULeuven, Rega Institute for Medical Research, Department of Microbiology and Immunology, Leuven, Belgium

DOP050

Serum proteomic analysis defines novel circulating inflammatory markers for Crohn's disease and response to anti-TNF therapy

Year: 2017
Source:

1KULeuven, Translational Research in Gastrointestinal Disorders (TARGID), Clinical and Experimental Medicine, Leuven, Belgium 2KULeuven, Laboratory of Hepatology, Clinical and Experimental Medicine, Leuven, Belgium 3UZLeuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 4KULeuven, Rega Institute for Medical Research, Department of Microbiology and Immunology, Leuven, Belgium

Authors:

Korf H.*1,2, Sabino J.1, Ballet V.3, de Bruyn M.1,4, Van Assche G.3, Ferrante M.3, Vermeire S.3

DOP050

The efficacy of vedolizumab by disease activity and prior tumour necrosis factor-alpha antagonist failure in patients with ulcerative colitis or Crohns disease: post-hoc analyses from the GEMINI 1 and GEMINI 2 studies

Year: 2016
Authors:

G. D’Haens1, J.-F. Colombel*2, M. Dubinsky2, B. Abhyankar3, A. James3, K. Lasch4

1Academic Medical Centre, Amsterdam, Netherlands, 2Icahn School of Medicine at Mount Sinai Hospital, New York, New York, United States, 3Takeda Development Centre Europe Ltd, London, United Kingdom, 4Takeda Pharmaceuticals USA, Inc, Deerfield, Illinois, United States

DOP051

Response and remission rates with up to 3 years of vedolizumab treatment in patients with ulcerative colitis

Year: 2016
Authors:

E.V. Loftus Jr1, J.-F. Colombel*2, A. Previtali3, M. Smyth3

1Mayo Clinic, Rochester, Minnesota, United States, 2Icahn School of Medicine at Mount Sinai Hospital, New York, New York, United States, 3Takeda Development Centre Europe Ltd, London, United Kingdom

1University Medical Center Groningen, University of Groningen, Department of Gastro-enterology and Hepatology, Groningen, Netherlands 2University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, Netherlands 3Nordic Bioscience, Biomarkers and Research, Herlev, Denmark 4Odense University Hospital, Department of Medical Gastroenterology, Odense, Denmark

DOP051

Serological biomarkers of tissue turnover can early identify responders to infliximab in Crohn's disease

Year: 2017
Source:

1University Medical Center Groningen, University of Groningen, Department of Gastro-enterology and Hepatology, Groningen, Netherlands 2University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, Netherlands 3Nordic Bioscience, Biomarkers and Research, Herlev, Denmark 4Odense University Hospital, Department of Medical Gastroenterology, Odense, Denmark

Authors:

van Haaften W.T.*1,2, Mortensen J.H.3, Olesen M.L.3,4, Karsdal M.A.3, Olinga P.2, Bay-Jensen A.-C.3, Dijkstra G.1

DOP052

Ozanimod induces histological response and remission: results from the TOUCHSTONE study, a randomised, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate-to-severe ulcerative colitis

Year: 2016
Authors:

W. Sandborn*1, B. Feagan2, G. D’Haens3, B. Levesque4, R. Pai5, S. Hanauer6, D. Wolf7, S. Vermeire8, S. Ghosh9, H. Smith10, M. Cravets10, P. Frohna10, S. Gujrathi10, R. Aranda10, A. Olson10

1University of California San Diego, Division of Gastroenterology, La Jolla, California, United States, 2Western University/Robarts Research Institute, Robarts Clinical Trials Inc., London, Ontario, Canada, 3Academic Medical Centre (AMC), Amsterdam, Netherlands, 4Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada, 5Mayo Clinic, Scottsdale, Arizona, United States, 6Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States, 7Atlanta Gastroenterology Associates, Atlanta, Georgia, United States, 8University of Leuven, Leuven, Belgium, 9University of Calgary, Calgary, Canada, 10Receptos, Inc., San Diego, California, States

DOP053

Effects of oral tofacitinib on patient-reported outcomes in patients with moderate-to-severe Crohns disease: results of 2 Phase 2b randomised placebo-controlled trials

Year: 2016
Authors:

J. Panés*1, M. Moscariello2, E. Maller2, G. Chan2, W. Wang2, P. Healey3

1Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 2Pfizer Inc, Collegeville, United States, 3Pfizer Inc, Groton, Connecticut, United States

1University of Michigan Medical School, Department of Microbiology and Immunology, Ann Arbor, United States 2Janssen Research & Development, LLC, Spring House, United States

DOP053

The fecal microbiome as a tool for monitoring and predicting response outcomes in ustekinumab-treated, anti-TNFα refractory Crohn's disease patients: results from the CERTIFI study

Year: 2017
Source:

1University of Michigan Medical School, Department of Microbiology and Immunology, Ann Arbor, United States 2Janssen Research & Development, LLC, Spring House, United States

Authors:

Doherty M.K.*1, Koumpouras C.1, Telesco S.E.2, Monast C.2, Brodmerkel C.2, Schloss P.D.1

DOP054

Discrepancies between patient-reported outcomes, endoscopic, and histologic appearance in ulcerative colitis

Year: 2016
Authors:

J.-F. Colombel*1, M. Keir2, A. Scherl2, R. Zhao2, G. de Hertogh3, W. Faubion4, T. Lu2

1Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York, United States, 2Genentech, South San Francisco, California, United States, 3Department of Imaging and Pathology, Catholic University of Leuven, Leuven, Belgium, 4Mayo Clinic Rochester, Department of Gastoenterology, Rochester, Minnesota, United States

1Safra Children's Hospital, Department of Pediatric Gastroenterology, Tel Hashomer, Israel 2Shaare Zedak Medical Center, Jerusalem, Israel

DOP054

High-throughput sequencing of T cell receptors from pediatric ulcerative colitis patients reveals distinct tissue-specific repertoires

Year: 2017
Source:

1Safra Children's Hospital, Department of Pediatric Gastroenterology, Tel Hashomer, Israel 2Shaare Zedak Medical Center, Jerusalem, Israel

Authors:

Werner L.1, Nunberg M.1, Haberman Y.1, Lahad A.1, Turner D.2, Weiss B.1, Shouval D.*1

DOP055

Azithromycin based therapy for induction of remission in mild to moderate active paediatric Crohns disease: the Multicentre azithromycin for Crohns disease AZCRO trial

Year: 2016
Authors:

A. Levine*1, 2, J. Kierkuś3, M. Kori4, M. Sladek5, R. Sigall Boneh1, J. Escher6, E. Wine7, B. Yerushalmi8, J. Amil Dias9, R. Shaul10, A. Akriv11, D. Zucker11, D. Turner11, 12

1Wolfson Medical Centre, Paediatric Gastroenterology and Nutrition Unit, Tel-Aviv, Israel, 2Tel Aviv University, Tel-Aviv, Israel, 3The Children’s Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland, 4Kaplan Medical Centre, Paediatric Day Care Unit, Rehovot, Israel, 5Jagiellonian University Medical College, Department of Paediatrics, Gastroenterology and Nutrition, Cracow, Poland, 6Erasmus MC-Sophia Children’s Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, 7University of Alberta, Division of Paediatric Gastroenterology, Department of Paediatrics, Edmonton, Canada, 8Soroka Medical Centre, Ben Gurion University of the Negev, Paediatric Gastroenterology, Beer-Sheva, Israel, 9Hospital, S. João, Department of Paediatrics, Porto, Portugal, 10Meyer Children’s Hospital, Gastroenterology Unit, Haifa, Israel, 11The Hebrew University of Jerusalem, Jerusalem, Israel, 12Shaare Zedek Medical Centre, The Juliet Keidan Institute of Paediatric Gastroenterology & Nutrition, Jerusalem, Israel

DOP056

Pharmacokinetics and exposure-response relationships of golimumab in paediatric patients with moderate-to-severe ulcerative colitis: results from a multicentre open-label study

Year: 2016
Authors:

O. J. Adedokun*1, D. Chan1, L. Padgett1, Y. Xu1, J. Hyams2, D. Turner3, Z. Xu1, H. Davis1, R. Strauss1

1Janssen R & D, LLC, Spring House, Pennsylvania, United States, 2Connecticut Children’s Medical Centre, Hartford, Connecticut, United States, 3The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Shaare Zedek Medical Centre, Jerusalem, Israel

DOP057

Tailored step-up approach results in beneficial long-term disease outcome in the prospective Belgian registry of paediatric Crohns disease (BELCRO)

Year: 2016
Authors:

L. Wauters*1, F. Smets2, E. De Greef3, I. Hoffman4, P. Bontems5, S. Van Biervliet6, I. Paquot7, P. Alliet8, W. Arts9, M. De Vos10, P. Bossuyt11, J.-F. Rahier12, O. Dewit13, T. Moreels13, D. Franchimont14, V. Muls14, F. Fontaine15, E. Louis15, J.-C. Coche16, B. Hauser3, H. Peeters17, E. Van de Vijver18, F. Baert19, S. Vermeire1, G. Veereman3

1UZ Leuven, Gastroenterology and Hepatology, Leuven, Belgium, 2UCL St Luc, Paediatric Gastroenterology, Brussels, Belgium, 3UZ Brussel, Paediatric Gastroenterology, Brussels, Belgium, 4UZ Leuven, Paediatric Gastroenterology, Leuven, Belgium, 5HUDERF, Paediatric Gastroenterology, Brussels, Belgium, 6UZ Gent, Paediatric Gastroenterology, Ghent, Belgium, 7CHC Liège, Paediatric Gastroenterology, Liège, Belgium, 8Jessa ziekenhuis, Paediatric Gastroenterology, Hasselt, Belgium, 9ZOL Genk, Paediatric Gastroenterology, Genk, Belgium, 10UZ Gent, Gastroenterology, Ghent, Belgium, 11Imelda ziekenhuis, Gastroenterology, Bonheiden, Belgium, 12UCL Mont Godinne, Gastroenterology, Mont Godinne, Belgium, 13UCL St Luc, Gastroenterology, Brussels, Belgium, 14ULB Erasme, Gastroenterology, Brussels, Belgium, 15CHU Liège, Gastroenterology, Liège, Belgium, 16St Pierre, Gastroenterology, Ottignies, Belgium, 17ST Lucas, Gastroenterology, Ghent, Belgium, 18UZ Antwerpen, Paediatric Gastroenterology, Antwerp, Belgium, 19Heilig Hart Ziekenhuis, Gastroenterology, Roeselaere, Belgium

DOP058

Long-term avoidance of steroids associated with exclusive enteral nutrition as induction therapy in paediatric Crohns disease does not increase surgery, hospitalisations or biologics use: results of a propensity score-matched cohort analysis

Year: 2016
Authors:

S. Basseri1, J. Connors2, A. Grant2, B. MacIntyre2, N. Giffin1, G. Mahdi2, A. Noble2, M. Rashid2, A. R. Otley2, J. Van Limbergen*2

1Dalhousie University, Halifax, Canada, 2IWK Health Centre, Halifax, Canada

DOP059

Efficacy of exclusive enteral nutrition in adult active Crohns disease with complications or failure of medical treatment

Year: 2016
Authors:

Q. Yang, X. Gao*, M. Zhi, H. Chen, N. Ding, S. Hu, J. Guo, P. Hu

The Sixth Affiliated Hosptial, Sun Yan-sen University, Department of Gastroenterology, Guangzhou, China

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 146 ()